---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-24-000025"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:48:37.850063+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience secures up to $11.7M convertible loan from Wellcome for ALTO-100 Phase 2b trial

## Summary
- Up to $11.663M convertible loan from Wellcome Trust; $2M funded immediately, remainder upon milestones.
- Interest accrues at SONIA+2%; convertible into common stock at 20% discount to 30-day VWAP after 2nd anniversary.
- Conversion shares capped at 5,363,326 (19.9% of outstanding stock).
- Proceeds used exclusively to fund ALTO-100 Phase 2b clinical trial in bipolar depression.

## SEC filing metadata
- accession: 0001999480-24-000025
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000025/0001999480-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000025/alto-20240724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-24-000025
- JSON: https://secwatch.observer/filing/0001999480-24-000025.json
- Plain text: https://secwatch.observer/filing/0001999480-24-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.